American Marconi Wireless News - Cannabis's MSO's Perfect Storm: Class Actions, RICO & Insurance Denials?

WASHINGTON, D.C. / ACCESS Newswire / August 24, 2026 / A high-stakes legal storm is converging around the American cannabis industry. While major multistate operators (MSOs) face sweeping federal consumer class actions and RICO claims over health and therapeutic marketing, an insurance carrier has launched a parallel fight in federal court over who should foot the bill.

The Core Conflict: Marketing Claims Meet Federal Scrutiny

On May 4, 2026, two major proposed class actions were filed against top-tier cannabis companies:

• The Illinois Action (Murray v. Cresco Labs Inc. et al.): Over 40 consumers filed a 320-page complaint in the U.S. District Court for the Northern District of Illinois targeting Cresco Labs, Green Thumb Industries, and Verano Holdings.

• The Connecticut Action (Duke v. Curaleaf Holdings Inc.): 18 plaintiffs filed a separate suit against Curaleaf in the U.S. District Court for the District of Connecticut.

Both lawsuits invoke the federal Racketeer Influenced and Corrupt Organizations Act (RICO), alongside state consumer-protection laws, alleging that operators deceptively marketed cannabis products as treatments for conditions like anxiety, depression, pain, and PTSD without FDA approval, while downplaying risks such as cannabis-use disorder and cardiovascular impacts.

Note: No court has found any of the defendants liable, and these claims remain unproven allegations.

The Insurance Battleground

Adding a critical financial dimension, Palomar Excess & Surplus Insurance Company filed a federal declaratory-judgment action on August 14, 2026, asking the court to determine whether its policies require it to defend or indemnify Cresco against these class-action claims.

While no court has ruled that Cresco lacks coverage, the move underscores a looming existential dread for the industry: What happens if aggressive consumer litigation falls outside the scope of expected insurance protections? If insurers successfully disclaim coverage, operators could be left entirely on the hook for mounting defense costs and potential liabilities.

The Regulatory Paradox: "Medical Marijuana" vs. FDA Standards

This litigation arrives at a paradoxical moment. Even as Washington moves toward recognizing marijuana as having a "currently accepted medical use" (CAMU) to remove it from Schedule I based on widespread state-level use, consumer plaintiffs are drawing a hard line against unverified therapeutic marketing.

The fundamental gap comes down to a definition:

• Widespread medical acceptance relies on aggregate state program experiences.

• Traditional FDA approval requires strict clinical trials proving a specific formula, dose, and manufacturing consistency are safe and effective for a targeted indication.

The MMJ International Holdings Connection

For MMJ International Holdings (MMJIH)-which has spent over eight years pursuing the formal FDA pharmaceutical pathway for cannabinoid medicines targeting Huntington's disease and multiple sclerosis-these lawsuits validate its long-standing warnings about marketplace discrepancies.

MMJ previously identified Cresco, Green Thumb, and Verano as commercial competitors in its own separate D.C. Circuit litigation, contrasting their commercial models with its rigorous investigational drug development. Now, independent consumer class actions are challenging those same companies over their marketing practices.

"The cannabis industry has spent months talking about Schedule III, tax relief, and expansion," said Duane Boise, CEO of MMJ International Holdings. "But these lawsuits expose the other side of calling marijuana medicine. Who proves what a product treats? Who establishes the dose? Who establishes manufacturing consistency? Who determines the warnings? And if those representations are challenged in court, who ultimately bears the liability? Those are questions the pharmaceutical regulatory system was created to answer."

As these federal class actions, RICO hurdles, and insurance disputes move forward, the legal landscape for commercial cannabis is growing sharply more complex.

About MMJ International Holdings, Inc.

MMJ International Holdings, Inc. is a privately held pharmaceutical company developing standardized cannabinoid-based investigational medicines through federal pathways administered by the FDA and DEA. MMJ's product candidates are investigational, have not been approved by the FDA, and remain subject to regulatory requirements.

CONTACT:
Madison Hisey
[email protected]
203-231-8583

Disclaimer: The allegations described in Murray v. Cresco and Duke v. Curaleaf are unproven claims made by plaintiffs. MMJ takes no position on the liability of any defendant.

SOURCE: MMJ International Holdings

View the original press release on ACCESS Newswire

P.Costa--AMWN